Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

References

• Dohner H, Stilgenbauer S, Benner A, . Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Hamblin T, Davis Z, Gardiner A, . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848–1854.
   PubMed Web of Science ®Google Scholar
• Damle RN, Wasil T, Fais F, . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840–1847.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry TS, . ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944–4951.
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, . Chronic lymphocytic leukemias utilizing the VH3–21 gene display highly restricted Vlambda2–14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003;101:4952–4957.
   PubMed Web of Science ®Google Scholar
• Zent CS, Kay NE.Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. Leuk Lymphoma 2011;52:1425–1434.
   PubMed Web of Science ®Google Scholar
• Pepper C, Majid A, Lin TT, . Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol 2012; 156:499–507.
   PubMed Web of Science ®Google Scholar
• Dighiero G, Maloum K, Desablens B, . Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998;338:1506–1514.
   PubMed Web of Science ®Google Scholar
• Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst 1999;91:861–868.
   PubMedGoogle Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, . Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, . Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood 2007;109:405–411.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, . Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:481–488.
   Google Scholar
• Zent CS, Call TG, Shanafelt TD, . Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008;113:2110–2118.
   PubMed Web of Science ®Google Scholar
• Zent CS, Secreto CR, Laplant BR, . Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008;32:1849–1856.
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA.Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008;20:444–449.
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O'Brien S, . Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413–3415.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Patton D, Gordon L, . A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). Leuk Lymphoma 2004;45:2269–2273.
   PubMed Web of Science ®Google Scholar
• Golay J, Manganini M, Rambaldi A, . Effect of alemtuzumab on neoplastic B cells. Haematologica 2004;89:1476–1483.
   PubMed Web of Science ®Google Scholar
• Siders WM, Shields J, Garron C, . Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma 2010;51:1293–1304.
   PubMed Web of Science ®Google Scholar
• Auffray C, Sieweke MH, Geissmann F.Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009;27:669–692.
   PubMed Web of Science ®Google Scholar
• Voso M, Pantel G, Rutella S, . Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002;87:918–925.
   PubMed Web of Science ®Google Scholar
• Cartron G, Zhao-Yang L, Baudard M, . Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 2008;26:2725–2731.
   PubMed Web of Science ®Google Scholar
• Ferrajoli A.Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:514–516.
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Hodnefield JM, . Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc 2008;83:776–785.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Grever M, . National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990–4997.
   PubMed Web of Science ®Google Scholar
• Goldin LR, Lanasa MC, Slager SL, . Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. Br J Haematol 2010;151:152–158.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Kay NE, Jenkins G, . B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 2009;113:4188–4196.
   PubMed Web of Science ®Google Scholar
• Fleming TR.One sample multiple testing procedures for phase II clinical trials. Biometrics 1982;38:143–151.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P.Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Abruzzo LV, Rosales CM, Medeiros LJ, . Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26:630–636.
   PubMed Web of Science ®Google Scholar
• Sohani AR, Ferry JA, Chang PS, . Epstein-Barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia. J Clin Oncol 2010;28:e69–e72.
   PubMed Web of Science ®Google Scholar
• Tadmor T, Attias D, Polliack A.Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy. Br J Haematol 2011;153:557–567.
   PubMed Web of Science ®Google Scholar
• Seiffert M, Schulz A, Ohl S, . Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro and present at abnormally high levels in vivo. Blood 2010;116:4223–4230.
   PubMed Web of Science ®Google Scholar
• Gustafson MP, Abraham RS, Lin Y, . Association of an increased frequency of CD14(+) HLA-DR(lo/neg) monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol 2012;156:674–676.
   PubMed Web of Science ®Google Scholar
• Lin TS, Flinn IW, Lucas MS, . Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia 2005;19:1207–1210.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Villamor N, Ritgen M, . International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956–964.
   PubMed Web of Science ®Google Scholar